Evidence map›Paper›PMID 36810520›Full record

ReviewAntibodies (Basel, Switzerland)2023

Non-Affinity Purification of Antibodies.

Tsutomu Arakawa, Yui Tomioka, Masataka Nakagawa, Chiaki Sakuma, Yasunori Kurosawa, Daisuke Ejima, Kouhei Tsumoto, Teruo Akuta

Abstract readReview
In one paragraph

Review in Antibodies (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Antibody Aggregate Removal by Multimodal Chromatography.Molecules (Basel, Switzerland) · 2025
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tsutomu ArakawaAlliance Protein Laboratories, San Diego, CA 92130, USA.
Yui TomiokaResearch and Development Division, Kyokuto Pharmaceutical Industrial Co., Ltd., Tahahagi 318-0004, Japan.
Masataka NakagawaResearch and Development Division, Kyokuto Pharmaceutical Industrial Co., Ltd., Tahahagi 318-0004, Japan.
Chiaki SakumaResearch and Development Division, Kyokuto Pharmaceutical Industrial Co., Ltd., Tahahagi 318-0004, Japan.
Yasunori KurosawaResearch and Development Division, Kyokuto Pharmaceutical Industrial Co., Ltd., Tahahagi 318-0004, Japan.
Daisuke EjimaBio-Diagnostic Reagent Technology Center, Sysmex Corporation, Sayama 350-1332, Japan.
Kouhei TsumotoDepartment of Bioengineering, School of Engineering, The University of Tokyo, Tokyo 113-8656, Japan.
Teruo AkutaResearch and Development Division, Kyokuto Pharmaceutical Industrial Co., Ltd., Tahahagi 318-0004, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, purification of antibodies is mainly carried out using a platform technology composed primarily of Protein A chromatography as a capture step, regardless of the scale. However, Protein A chromatography has a number of drawbacks, which are summarized in this review. As an alternative, we propose a simple small-scale purification protocol without Protein A that uses novel agarose native gel electrophoresis and protein extraction. For large-scale antibody purification, we suggest mixed-mode chromatography that can in part mimic the properties of Protein A resin, focusing on 4-Mercapto-ethyl-pyridine (MEP) column chromatography.

Indexed as

activated carbonagaroseantibodyMEPmixed-modenon-affinityProtein Apurificationsalting-out

Identifiers

PMID36810520
PMCPMC9944463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.